In a story in the Spring 2018 issue of PTSDJournal Magazine about Tonix Pharmaceuticals and its current drug in development, Tonmya*, the writer referenced a comparison to Viagra. PTSDJournal wants to clarify that this was an inaccurate reference and mischaracterization of Tonmya.
It’s our duty to inform our readers with factual content and to never mischaracterize a subject. In this case we failed to uphold that standard. It’s important to us that our readers and subjects are portrayed in a positive and accurate light.
*Tonmya has been conditionally accepted by the U.S. Food and Drug Administration (FDA) as the proposed trade name for TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for PTSD. TNX-102 SL is an investigational new drug and has not been approved for any indication.